S-1: United Health Products Faces FDA Hurdles, Secures New Funding

United Health Products, Inc. is navigating significant FDA regulatory challenges for its CelluSTAT hemostatic gauze while securing up to $4 million in new financing from Alumni Capital LP.

Summary

• United Health Products, Inc. (UHP) develops, manufactures, and markets CelluSTAT, a patented hemostatic gauze derived from cotton, for healthcare and wound care sectors.
• The company is actively seeking FDA Premarket Approval (PMA) for its CelluSTAT product for use in U.S. Class III human surgical markets, which represents its primary business strategy.
• UHP has a history of operating losses, with a net loss of $2,132,440 for the nine months ended September 30, 2025, and $2,001,733 for the year ended December 31, 2024.
• The company reported $0 in revenue for all periods presented, as capital and resources are focused on obtaining Class III PMA.
• UHP has a negative working capital of $1,963,227 as of September 30, 2025, and limited cash on hand at $18,376.
• The FDA issued a Warning Letter on March 25, 2025, citing five regulatory violations during UHP's 2019 clinical trial, including failure to seek an Investigational Device Exemption.
• UHP is in discussions with the FDA regarding solutions, including potentially conducting a new pivotal clinical trial and seeking partners to sponsor the study.
• The company entered into a Securities Purchase Agreement with Alumni Capital LP on December 16, 2025, for a $289,267 convertible note, providing net proceeds of $250,000.
• UHP also entered into an Any Market Purchase Agreement (AMPA) with Alumni Capital LP on December 16, 2025, allowing UHP to sell up to $4,000,000 of common stock to Alumni.
• A Commitment Warrant was issued to Alumni Capital LP to purchase up to 3,484,321 shares of common stock at $0.07462 per share.
• The company's independent registered public accounting firm has expressed substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative due to severe financial distress (recurring losses, negative working capital, minimal cash, going concern doubt) and significant regulatory setbacks (FDA Warning Letter, uncertain resolution timeline, potential need for new clinical trials). While new financing has been secured, it is primarily for resale by an investor and the company still needs additional capital. The core business strategy is heavily reliant on a highly uncertain FDA approval process.

Positives

• UHP's CelluSTAT product has a 510(k) FDA approval since 2012 for superficial use, indicating existing regulatory clearance for certain applications.
• A 2019 clinical trial showed CelluSTAT's statistically superior performance in time to hemostasis over Ethicon's Surgicel Original, a current standard of care, with no attributable adverse events.
• The company has secured new financing arrangements with Alumni Capital LP, including a $250,000 convertible note and access to up to $4,000,000 through an Any Market Purchase Agreement.
• UHP's hemostatic gauze technology is protected by U.S. patents running through 2029, and the company holds several registered trademarks for its product formats.
• Management is actively evaluating strategic alternatives, including potential sale or merger with an industry leader, or commercial partnerships, to maximize shareholder value.

Negatives

• UHP has a history of recurring operating losses, with a net loss of $2,132,440 for the nine months ended September 30, 2025, an increase from $1,187,621 in the comparable prior period.
• The company has generated no revenue in the periods presented (three and nine months ended September 30, 2025 and 2024, and years ended December 31, 2024 and 2023).
• UHP has a negative working capital of $1,963,227 and minimal cash ($18,376) as of September 30, 2025, indicating significant liquidity challenges.
• The FDA issued a Warning Letter on March 25, 2025, identifying five regulatory violations during the 2019 clinical trial, which must be addressed before a revised PMA application can be submitted.
• The timing to resolve the FDA Warning Letter is uncertain, and the company may not proceed with a new clinical study until its resolution.
• The company's independent registered public accounting firm has expressed substantial doubt about its ability to continue as a going concern.
• UHP is currently dependent on a single hemostatic gauze product for future income, posing a concentration risk.
• The company currently lacks director and officer liability insurance, which may hinder its ability to attract and retain qualified personnel.

Risks

• It is not possible to predict the actual number of shares sold to Alumni under the AMPA or the actual gross proceeds, limiting the certainty of cash resources.
• The terms of the AMPA limit the total value of shares that may be issued to Alumni, potentially restricting the company's ability to enhance cash resources.
• Management will have broad discretion over the use of net proceeds from sales to Alumni under the AMPA, which may not yield a favorable return.
• There is no assurance that the FDA will approve the Class III application for CelluSTAT for internal surgical procedures, which is critical to the primary business strategy.
• No assurances can be given that plans to penetrate certain market segments will be successful, or that ongoing discussions with potential commercial partners and acquirers will result in a specific transaction.
• Additional financing will be needed to execute the business plan and fund operations, and there is no assurance it will be available on acceptable terms, or at all, potentially leading to cessation of operations.
• There is no guarantee of market acceptance for the CelluSTAT product, which is essential for generating adequate revenues.
• Dependence on commercial relationships for operations and strategy implementation, with no current relationships established, poses a risk to business prospects.
• Difficulties in the supply chain, particularly with manufacturing, packaging, and sterilization in Asia and the United States, could disrupt deliveries and revenue generation.
• The company is dependent on one hemostatic gauze product, and the failure to develop a commercial market or the introduction of superior competing technologies could adversely affect operations.
• Inability to attract and retain talented personnel, especially a small management team, could adversely affect the business.
• Inability to adequately protect technologies or intellectual property rights, including patent challenges or expiration, could adversely affect the business.
• Material weaknesses in internal control over financial reporting could affect timely and accurate reporting, potentially leading to future restatements or a decline in stock price.
• Extensive regulation by the FDA and other governmental entities, including compliance costs and potential enforcement actions, could harm the business.
• The healthcare industry's extensive government regulation can result in increased costs, delays, limits on operating flexibility, and competitive disadvantages.
• Failure to comply with laws or government regulations could result in penalties and affect expansion into new or existing markets.
• Compliance with federal securities laws and Sarbanes-Oxley Act requirements is expensive and time-consuming, potentially requiring additional personnel.
• Lack of director and officer liability insurance may make it difficult to attract and retain qualified officers and directors.
• Stockholders face risks of dilution from additional share issuances, including those for consultants and future capital raises.
• The stock price may be highly volatile due to various factors, many beyond the company's control.
• The company has not paid dividends and does not expect to, limiting return on investment to stock price appreciation.
• There is no established market for the common stock, and it is deemed a penny stock, making it more difficult for investors to sell shares.
• Offers or availability for sale of a substantial number of shares could cause the stock price to decline due to an 'overhang' effect.

Future Outlook

The company's primary future outlook is contingent on obtaining FDA Premarket Approval (PMA) for its CelluSTAT product for Class III human surgical markets. While actively addressing FDA deficiencies and a Warning Letter, the company is evaluating strategic alternatives such as a sale or merger with an industry leader, or commercial partnerships, rather than pursuing full commercialization independently. There is no assurance that PMA will be granted or that any strategic transaction will occur on favorable terms. The company will need additional financing to fund operations and execute its business plan, which may not be available.

Management Comments

• We are continuing on our path to seek FDA Premarket Approval (PMA) for our CelluSTAT Hemostatic Gauze products to implement our business strategy.
• The 2019 clinical trial involving 236 patients showed statistically superior performance in time to hemostasis using CelluSTAT over Ethicon's Surgicel Original, the current standard of care.
• None of the adverse events that occurred during the 2019 study were attributable to our hemostatic gauze product.
• The Class III human surgical markets, both domestic and international, represent the most attractive market for our products due to the smaller number of competitors and resulting premium pricing.
• We believe that our extensive laboratory testing and our completed human trial indicate that the CelluSTAT technology could successfully compete against established Class III market participants, and could gain a significant market share.
• We do not intend to pursue the full commercialization of our products independently nor to remain an independent company in the long term.
• We are discussing with the FDA various solutions including, among other options, conducting a new pivotal clinical trial that will yield sufficient data to confirm the safety and effectiveness of our product without reliance on data from the 2019 study.
• We are also in discussions and negotiation with suitable partners to serve as substitute sponsor for this study while we address and resolve the Warning Letter.

Industry Context

United Health Products operates in the highly regulated and competitive wound care and medical device sectors. The market for hemostatic products, particularly Class III devices for internal surgical use, is concentrated among large, established companies with significantly greater capital and operational resources. UHP's strategy to penetrate the Class III market, if successful, could offer premium pricing due to limited competition in that specific segment. However, the extensive regulatory hurdles, as evidenced by the FDA's Deficiencies Letter and Warning Letter, highlight the significant challenges smaller companies face in gaining market access against entrenched players like Ethicon (Johnson & Johnson). The company's pursuit of strategic partnerships or an acquisition reflects a common trend for smaller innovators seeking to leverage the distribution and financial strength of larger industry participants to commercialize their products.

Comparison to Industry Standards

• CelluSTAT demonstrated statistically superior performance in time to hemostasis compared to Ethicon's Surgicel Original in a 2019 clinical trial, indicating a potential competitive advantage in efficacy.
• The FDA's request for more data for intestinal and thoracic organ space procedures suggests that CelluSTAT's current data, while showing superiority in general hemostasis, may not fully meet the stringent safety and effectiveness requirements for all Class III surgical applications, unlike established products that have already cleared these hurdles.
• The company's reliance on contract manufacturing and third-party sterilization is a common practice in the medical device industry, but potential supply chain difficulties could impact its ability to compete with larger companies that may have more integrated or diversified manufacturing capabilities.
• UHP's current financial position, characterized by recurring losses and negative working capital, contrasts sharply with the robust financial health and R&D budgets of industry leaders like Baxter International, Becton Dickinson & Company, and Johnson & Johnson, making independent commercialization challenging.

Management Changes

Corporate Governance

Legal Proceedings

• The SEC investigation of the company, initially reported in the 2021 Annual Report, was settled on June 15, 2022, through a consent judgment without admitting or denying allegations. The company was required to pay a civil penalty of $450,000, which was fully paid by December 31, 2023.
• A 2018 lawsuit filed by Philip Forman against the company and its former CEO was settled effective March 31, 2023, by issuing 1,850,000 shares of common stock with a fair value of $462,500.

Related Party Transactions

• Brian Thom (CEO) converted $372,000 of a loan payable balance to a convertible note payable in 2022, with 10% interest (increased to 13% in 2024) and maturity extended to December 31, 2026. Accrued interest was $191,919 as of September 30, 2025.
• Robert Denser (Director) loaned the company $93,000 through a convertible note in 2022, with 10% interest (increased to 13% in 2024) and maturity extended to December 31, 2026. Accrued interest was $41,923 as of September 30, 2025.
• On October 14, 2025, the company issued a non-interest bearing promissory note to Brian Thom for $250,000 to fund private placement expenses and general corporate purposes, due February 14, 2026.
• During the nine months ended September 30, 2025, Brian Thom advanced the company $20,000 for operating expenses, which was unsecured, non-interest bearing, and due on demand, and was subsequently repaid.
• In 2023, the company issued 1,204,688 shares of common stock with a fair value of $271,031 to its officers and management to settle $218,250 of accrued compensation, resulting in a $52,781 loss on settlement of debt.

Stakeholder Impact

• Shareholders face significant dilution risk from the potential issuance of up to 25,669,288 shares to Alumni Capital LP, as well as future equity financings needed to fund operations.
• Existing shareholders' investment return is limited to stock price appreciation, as the company has never paid dividends and does not expect to in the foreseeable future.
• The 'going concern' doubt and recurring losses indicate a high risk of further value erosion for shareholders and potential cessation of operations if additional financing is not secured.
• Employees and management face uncertainty regarding the company's long-term viability and the need to attract and retain talented personnel, especially given the lack of D&O liability insurance.
• Customers (potential) for CelluSTAT face uncertainty regarding product availability and market acceptance, particularly for Class III surgical applications, due to ongoing FDA regulatory challenges.
• Creditors, including related parties holding convertible notes, face risks associated with the company's ability to repay its obligations given its negative working capital and recurring losses.
• Suppliers may face risks related to payment delays or disruptions due to the company's financial position and reliance on external financing.

Next Steps

• Address and resolve the FDA Warning Letter, potentially through modifications to existing CAPAs or newly developed CAPAs.
• Discuss with the FDA various solutions, including conducting a new pivotal clinical trial to confirm CelluSTAT's safety and effectiveness without relying on the 2019 study data.
• Negotiate with suitable partners to serve as substitute sponsors for a new clinical study.
• Evaluate paths to rapidly develop and grow revenue and profits in all target market segments, including potential sale or merger with an industry leader or commercial partnerships.
• Raise additional capital through various means, including commercial collaborations and debt or equity financings, to fund operations and execute the business plan.
• Continue to improve operational, information technology, and financial systems, infrastructure, procedures, and controls to address material weaknesses in internal control over financial reporting.
• Expand, train, retain, and manage the employee base.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by recurring net losses, zero revenue, negative working capital, minimal cash, and an explicit 'going concern' doubt from its auditors. The core business strategy, which relies on FDA Class III PMA for its CelluSTAT product, is significantly jeopardized by a recent FDA Warning Letter citing multiple regulatory violations in a key clinical trial. The resolution timeline for these regulatory issues is uncertain, and a new pivotal clinical trial may be required, incurring substantial delays and costs. While new financing arrangements with Alumni Capital LP provide some capital access, they also introduce significant dilution risk for existing shareholders, and the company still requires substantial additional funding. The stock is a 'penny stock' with high volatility and no established market, further increasing investment risk. Given the critical financial state, major regulatory setbacks, and high uncertainty regarding future operations and market access, a seasoned investor would likely recommend a strong sell.

Keywords

Hemostatic Gauze, CelluSTAT, FDA PMA, Medical Device, Wound Care, Surgical Market, Biotechnology, SEC Filing, Capital Raise, Going Concern, OTC Markets, Alumni Capital